KCA
Search
- Page Path
- HOME > Search
Original Articles
- Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Management of Malignant Pleural Effusion
- Kee Won Kim, Suk Young Park, Myung Sook Kim, Seok Chan Kim, Eun Hee Lee, So Young Shin, Jong Ho Lee, Jong Bum Kweon, Kuhn Park
- Cancer Res Treat. 2004;36(1):68-71. Published online February 29, 2004
- DOI: https://doi.org/10.4143/crt.2004.36.1.68
-
Abstract
PDF
PubReader
ePub Purpose The purpose of this study was to evaluate the efficacy of intrapleural chemotherapy (IPC) with cisplatin and cytarabine in the management of malignant pleural effusion (MPE) from non-small-cell lung cancer (NSCLC).
Materials and Methods A prospective analysis was carried out on 40 patients with pathologically proven MPE from NSCLC who had received IPC. A single dose of cisplatin 100 mg/m2 plus cytarabine 1200 mg/m2 in 250 ml normal saline was instilled into the pleural space via a chest tube and drained 4 hours later. Patients were evaluated for toxicities and responses at 1, 2, & 3 weeks and then at monthly intervals if possible. Systemic chemotherapy was administered, if the patient agreed to receive it, after achieving complete control (CC) of MPE.
Results The median duration of chest tube insertion for drainage was 7 (3~32) days. Among the assessable 37 patients, CC and partial control (PC) were 32 (86.5%) and 4 (10.8%) patients, respectively (overall response rate 97.3%). The median duration of response was 12 months (2~23) and there were only two relapses of IPC after achieving CC. Among the 35 patients who were assessable until they died, 28 patients (80.0%) maintained CC until the last follow-up. There was only one toxic death and the toxicities of IPC, versus the results obtained, were deemed acceptable.
Conclusion The procedures were tolerable to the patients and chemotherapy-induced complications were at an acceptable level. The outcome of this trial indicates that IPC has a superior and long lasting treatment response in the management of patients with MPE from NSCLC.
-
Citations
Citations to this article as recorded by
- Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef - Survival Benefits for Pulmonary Adenocarcinoma With Malignant Pleural Effusion After Thoracoscopic Surgical Treatment: A Real-World Study
Xin Li, Mingbiao Li, Jinshuang Lv, Jinghao Liu, Ming Dong, Chunqiu Xia, Honglin Zhao, Song Xu, Sen Wei, Zuoqing Song, Gang Chen, Hongyu Liu, Jun Chen
Frontiers in Oncology.2022;[Epub] CrossRef - Modified indwelling pleural catheter versus silver nitrate pleurodesis for the management of malignant pleural effusion
Mohammed F. Abdelghany, Khaled Essmat, Atef Farouk El-Karn, Sahar Farghly Youssif
The Egyptian Journal of Chest Diseases and Tuberculosis.2022; 71(2): 248. CrossRef - Chinese herbal injections versus intrapleural cisplatin for lung cancer patients with malignant pleural effusion: A Bayesian network meta-analysis of randomized controlled trials
Yi-Fang Xu, Yun-Ru Chen, Fan-Long Bu, Yu-Bei Huang, Yu-Xin Sun, Cheng-Yin Li, Jodi Sellick, Jian-Ping Liu, Dan-Mei Qin, Zhao-Lan Liu
Frontiers in Oncology.2022;[Epub] CrossRef - Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019;[Epub] CrossRef - Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion
Mohammad K. El Badrawy, Raed El-Metwally Ali, Asem A. Hewidy, Mohamed A. El-Layeh, Fatma M. F. Akl, Abdelhadi Shebl
Egyptian Journal of Bronchology.2018; 12(1): 98. CrossRef - Biodegradable drug-eluting pellets provide steady and sustainable cisplatin release in the intrapleural cavity: In vivo and in vitro studies
Yin-Kai Chao, Yu-Wen Wen, Kuo-Sheng Liu, Yi-Chuan Wang, Chih-Wei Wang, Shih-Jung Liu
International Journal of Pharmaceutics.2015; 484(1-2): 38. CrossRef
- Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
- 10,362 View
- 58 Download
- 7 Crossref
- Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Manabement of Malignant Pleural Effusion
- Suk Young Park, Baik Jong Seo
- J Korean Cancer Assoc. 1996;28(4):698-705.
-
Abstract
PDF
- Malignant pleural effusion is a common snd signigicant problem in patients with advanced malignancies. The optimal means of control are not defined. Pleurodesis with tetracycline or other sclerosing agents has been the usual treatment for malignant pleural effusions. Intracavitary cisplatin-based chemotherapy has been recently reported to be successful in some clinical trials for the purpose of controlling malignant exudate and favored by some authors because it is thought to be cytotoxic rather than sclerosing, that is, the potential advantage of treating the underlying malignancy in addition to controlling the effusion. This study evaluated intrapleural cisplatin and cytarabine combination chemotherapy in 15 patients with malignant pleural effusions from lung and other cancers. A single dose of cisplatin plus cytarabine was instilled into pleural space via a chest tube and drained 4 hours later. Systemic chemotheapy and/or radiation therapy were given at least 3 weeks apart after intrapleural chemotherapy if decided to recieve them. The outcome of this trial indicated that the intrapleural chemotherapy had high and durable treatment response(87%; CR 13 cases(81%)) and the median duration of response was 29 weeks which seemed long enough to be little maiignant pieural effusion in 7 cases among 9 patients followed up till moribund state. The procedures were tolerable in all the cases and chemothrapy induced complications were not significant.
- 3,089 View
- 20 Download
First
Prev
